Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
62 hedge funds and large institutions have $31.8M invested in Asterias Biotherapeutics Inc. Series A in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 7 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $32.6M → $31.8M (-$785K)
3% less funds holding
Funds holding: 64 → 62 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
58% less call options, than puts
Call options by funds: $241K | Put options by funds: $569K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$332K |
| 2 |
BlackRock
New York
|
+$175K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$70.3K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$59.3K |
| 5 |
VF
Virtu Financial
New York
|
+$49.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corrado Advisors
Ramsey,
New Jersey
|
-$63K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$58K |
| 4 |
SG Americas Securities
New York
|
-$57K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$34.4K |
AST Hedge Fund Activity: Q3 2017 in Review
62 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q3 2017, worth a combined $31.8M — down 2.4% from $32.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AST and 5 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 16 added.
The largest buyer was Vanguard Group, adding an estimated $332K. The largest seller was Corrado Advisors, exiting entirely with an estimated $63K sold.
- 62 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q3 2017, down from 64 in Q2 2017.
- Funds reported $31.8M of Asterias Biotherapeutics Inc. Series A stock for Q3 2017, down 2.4% quarter-over-quarter.
- 5 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q3 2017 and 7 closed out, a net change of -2 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q3 2017 was Vanguard Group, an estimated $332K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q3 2017 was Corrado Advisors, an estimated $63K sold.
Based on aggregated 13F filings for Q3 2017.